Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Jennifer Mooi"'
Autor:
Ismael A. Vergara, Christopher P. Mintoff, Shahneen Sandhu, Lachlan McIntosh, Richard J. Young, Stephen Q. Wong, Andrew Colebatch, Daniel L. Cameron, Julia Lai Kwon, Rory Wolfe, Angela Peng, Jason Ellul, Xuelin Dou, Clare Fedele, Samantha Boyle, Gisela Mir Arnau, Jeanette Raleigh, Athena Hatzimihalis, Pacman Szeto, Jennifer Mooi, Daniel S. Widmer, Phil F. Cheng, Valerie Amann, Reinhard Dummer, Nicholas Hayward, James Wilmott, Richard A. Scolyer, Raymond J. Cho, David Bowtell, Heather Thorne, Kathryn Alsop, Stephen Cordner, Noel Woodford, Jodie Leditschke, Patricia O’Brien, Sarah-Jane Dawson, Grant A. McArthur, Graham J. Mann, Mitchell P. Levesque, Anthony T. Papenfuss, Mark Shackleton
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
The genetic changes that occur in late stage metastatic melanoma are not well delineated. Here, the authors use rapid autopsy samples from metastatic melanoma patients and show that the late stage in the disease is characterised by whole genome doubl
Externí odkaz:
https://doaj.org/article/4c17fb9d0e02463397deea2b50e28d35
Autor:
David Pryor, Mathias Bressel, Nathan Lawrentschuk, Ben Tran, Jennifer Mooi, Jeremy Lewin, Arun Azad, Duncan Colyer, Nitika Neha, Mark Shaw, Sarat Chander, Paul Neeson, Daniel Moon, Katharine Cuff, Simon Wood, Declan G. Murphy, Shahneen Sandhu, Sherene Loi, Shankar Siva
Publikováno v:
Contemporary Clinical Trials Communications, Vol 21, Iss , Pp 100703- (2021)
Background: The management of oligometastatic clear cell renal cell carcinoma (ccRCC) varies widely, ranging from observation to resection or systemic therapies. Prolonged survival has been observed following resection or stereotactic ablative body r
Externí odkaz:
https://doaj.org/article/a72bf5877d9647c5b2a332450615226b
Autor:
Niall C. Tebbutt, John M. Mariadason, Effie Skrinos, Alysson Wann, Timothy J. Price, Rachel Wong, Stephen Brown, Geoffrey Chong, Jessica Da Gama Duarte, Peter Savas, Fiona Chionh, Jennifer Mooi
Supplementary Fig 2. Change in overall (A) and specific (B) plasma antibody titres against tumour antigens from baseline (D0) to 6 weeks of treatment (6W), n=8 patients.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a93307e3f49119d12ba7f7bd4af5b82
https://doi.org/10.1158/1078-0432.22483947
https://doi.org/10.1158/1078-0432.22483947
Autor:
Niall C. Tebbutt, John M. Mariadason, Effie Skrinos, Alysson Wann, Timothy J. Price, Rachel Wong, Stephen Brown, Geoffrey Chong, Jessica Da Gama Duarte, Peter Savas, Fiona Chionh, Jennifer Mooi
Supplementary Fig 3. Hierarchical clustering of plasma antibody profiles after 6 weeks of study treatment, using the Spearman rank correlation method with average linkage. Patient ID (0n) at the 6-week time point (best tumour response, PFS).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043fdea44cd56ce967dac93dc73fffd3
https://doi.org/10.1158/1078-0432.22483944
https://doi.org/10.1158/1078-0432.22483944
Autor:
Niall C. Tebbutt, John M. Mariadason, Effie Skrinos, Alysson Wann, Timothy J. Price, Rachel Wong, Stephen Brown, Geoffrey Chong, Jessica Da Gama Duarte, Peter Savas, Fiona Chionh, Jennifer Mooi
Supplementary tables 1-3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6716d476d43230054feab526474207c
https://doi.org/10.1158/1078-0432.22483938
https://doi.org/10.1158/1078-0432.22483938
Autor:
Niall C. Tebbutt, John M. Mariadason, Effie Skrinos, Alysson Wann, Timothy J. Price, Rachel Wong, Stephen Brown, Geoffrey Chong, Jessica Da Gama Duarte, Peter Savas, Fiona Chionh, Jennifer Mooi
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68f411c213a6e87d6ee96b2253f72a1a
https://doi.org/10.1158/1078-0432.22483941.v1
https://doi.org/10.1158/1078-0432.22483941.v1
Autor:
Amin Esmaeilniakooshkghazi, Eric Pham, Sudeep P. George, Afzal Ahrorov, Fabian R. Villagomez, Michael Byington, Srijita Mukhopadhyay, Srinivas Patnaik, Jacinta C. Conrad, Monali Naik, Saathvika Ravi, Niall Tebbutt, Jennifer Mooi, Camilla M. Reehorst, John M. Mariadason, Seema Khurana
Publikováno v:
The FASEB Journal. 37
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd7799a0f51eb17f801cdaa055d0c281
https://doi.org/10.1096/fj.202201454r
https://doi.org/10.1096/fj.202201454r
Autor:
Amin Esmaeilniakooshkghazi, Eric Pham, Sudeep P. George, Afzal Ahrorov, Fabian R. Villagomez, Michael Byington, Srijita Mukhopadhyay, Srinivas Patnaik, Jacinta C. Conrad, Monali Naik, Saathvika Ravi, Niall Tebbuttt, Jennifer Mooi, Camilla M Reehorst, John M. Mariadason, Seema Khurana
SummaryFascin1 expression in colorectal carcinomas (CRCs) is linked to a clinically aggressive disease with poor prognosis. Despite that fascin1’s role in the etiology of CRCs has not been directly investigated. We show fascin1 expression in one-th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::317b6b8c35383083b27b234688412694
https://doi.org/10.1101/2022.06.14.496198
https://doi.org/10.1101/2022.06.14.496198
Autor:
Muhammad Ali, Jennifer Mooi, Nathan Lawrentschuk, Rana R. McKay, Raquibul Hannan, Simon S. Lo, William A. Hall, Shankar Siva
Publikováno v:
European urology. 82(6)
Stereotactic ablative body radiotherapy (SABR) is an emerging treatment modality for primary and metastatic renal cell carcinoma (RCC).To review and summarise the evidence on the use of SABR in RCC in a narrative review.We performed an online search
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02788c36070be29b8a3de055a2203472
https://pubmed.ncbi.nlm.nih.gov/36041935
https://pubmed.ncbi.nlm.nih.gov/36041935
Autor:
Shankar Siva, Mathias Bressel, Simon T. Wood, Mark G. Shaw, Sherene Loi, Shahneen K. Sandhu, Ben Tran, Arun A. Azad, Jeremy H. Lewin, Katharine E. Cuff, Howard Y. Liu, Daniel Moon, Jeremy Goad, Lih-Ming Wong, Michael LimJoon, Jennifer Mooi, Sarat Chander, Declan G. Murphy, Nathan Lawrentschuk, David Pryor
Publikováno v:
European urology. 81(4)
Stereotactic ablative body radiotherapy (SABR) is an option for oligometastatic clear cell renal cell carcinoma (ccRCC) but is limited by a lack of prospective clinical trial data.The RAPPORT trial evaluated the safety and efficacy of total metastati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d75f49c17a7a32c4d712d1a862cb73a
https://pubmed.ncbi.nlm.nih.gov/35757922
https://pubmed.ncbi.nlm.nih.gov/35757922